Johnson & Johnson
Research Johnson & Johnson (JNJ) on Bullrun: valuation model: 5.5% overvalued, market cap USD 657.78B, P/E 31.7, dividend yield 2.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJNJ
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal5.5% overvalued
- Market capUSD 657.78B
- P/E31.7
- Dividend yield2.0%
- Financial periodQ2 2026
- RevenueUSD 25.31B
- Net incomeUSD 5.53B
- Free cash flowUSD 7.30B
- Gross margin68.2%
Valuation Snapshot
Bullrun's latest valuation model marks Johnson & Johnson as 5.5% overvalued; latest market cap is USD 657.78B; P/E is 31.7; dividend yield is 2.0%.
Peer valuation comparison
Latest P/E is 31.66x versus a Healthcare sector median of 24.46x (29.4% above).
Latest dividend yield is 1.99% versus a Healthcare sector median of 2.11% (5.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 94.19B | USD 26.80B | USD 19.70B | 67.9% | 11.03 | USD 19.71B | USD 47.94B | USD 81.54B |
| FY2024 | USD 88.82B | USD 14.07B | USD 19.84B | 69.1% | 5.79 | USD 24.11B | USD 36.65B | USD 71.49B |
| FY2023 | USD 85.16B | USD 35.15B | USD 18.25B | 68.8% | 13.72 | USD 21.86B | USD 29.38B | USD 68.77B |
| FY2022 | USD 78.74B | USD 20.88B | USD 19.76B | 70.3% | 7.81 | USD 14.49B | USD 33.79B | USD 74.02B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 657.78B | 31.7 | 2.4% | 6.58 |
| 2025 | 2025-12-31 | USD 498.32B | 18.7 | 2.5% | 5.14 |
| 2024 | 2024-12-31 | USD 348.09B | 24.9 | 3.4% | 4.91 |
| 2023 | 2023-12-29 | USD 377.32B | 29.9 | 3.0% | 4.7 |
| 2022 | 2022-12-30 | USD 461.85B | 24.6 | 2.5% | 4.45 |
| 2021 | 2021-12-31 | USD 450.36B | 21.9 | 2.4% | 4.19 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 6.58 USD, yield 2.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 5.14 USD |
| FY2024 | 4.91 USD |
| FY2023 | 4.7 USD |
| FY2022 | 4.19 USD |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Johnson & Johnson overvalued or undervalued?
Bullrun's valuation model currently marks Johnson & Johnson as 5.5% overvalued.
What is Johnson & Johnson's market cap?
Johnson & Johnson's market capitalization is USD 657.78B.
What is Johnson & Johnson's P/E ratio?
Johnson & Johnson's price-to-earnings (P/E) ratio is 31.7.
Does Johnson & Johnson pay a dividend?
Johnson & Johnson has a dividend yield of 2.0%.
What does Johnson & Johnson do?
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.